FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

			549
Washington.	D.C.	20549	

	OMB APPROVAL									
	OMB Number:	3235-0287								
Estimated average burden										
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

msuuc	cuon r(b).			riieu					company Act		34		Į.		
				2. Issuer Name <b>and</b> Ticker or Trading Symbol Aceragen, Inc. [ ACGN ]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
												X Director 10% Owner			
()					3. Date of Earliest Transaction (Month/Day/Year) 01/17/2023						Officer (give title X Other (specify below)  See Remarks				
										0.1.					
(Street) RALEIGH NC 27609				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person     Y     Form filed by More than One Reporting Person				
(City)	(;	State)	(Zip)								X	Form file	ed by More tr	nan One Repor	ting Person
		T	able I - Non-l	Deriva	tive S	Securiti	es Acc	quired, Di	sposed o	f, or Ben	eficially	Owned			
Date			action 2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed C		ies Acquired Of (D) (Instr	I (A) or : 3, 4 and 5)	5. Amount Securities Beneficiall Owned Fo	ly (D	orm: Direct	7. Nature of Indirect Beneficial Ownership			
							Code V	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 an	on(s) id 4)		(Instr. 4)	
			Table II - De						posed of, convertil			wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year) if any	Execution Date,	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	Ownershi Form:	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	1	
Warrant	\$460	01/17/2023		С			14,115	09/28/2022	03/23/2031	Series Z Preferred Stock	14,115	(1)(2)	0	D <sup>(3)</sup>	
Warrant	\$7.82	01/17/2023		С		830,294		01/17/2023	03/23/2031	Common Stock	830,294	(1)(2)	830,294	D(3)	
		f Reporting Person*  Nestment Fu	ınd XV, L.P.				,			,	,	,	,		,
(Last)	X FORKS I	(First)	(Middle)												
.200 517															
(Street)	SH	NC	27609												
(City)		(State)	(Zip)												

## **Explanation of Responses:**

1. Name and Address of Reporting Person\*

4208 SIX FORKS ROAD, SUITE 920

(First)

NC

(State)

(Middle)

27609

(Zip)

NQ POF V GP, Ltd.

- 1. On September 28, 2022, Issuer completed its merger ("Merger") with Aceragen, Inc. ("Aceragen"), in accordance with the terms of that certain Agreement and Plan of Merger, dated September 28, 2022 (the "Merger Agreement"). Pursuant to the Merger Agreement, NovaQuest Co-Investment Fund XV, L.P. ("NovaQuest") received warrants to purchase (i) 1,343,547 shares of Issuer Common Stock and (ii) 14,115 shares of Issuer non-voting, convertible Series Z Preferred Stock ("Series Z Preferred Stock").
- 2. On January 12, 2023, Issuer's stockholders approved the conversion of Issuer Series Z Preferred Stock into shares of Issuer Common Stock. Each share of Issuer Series Z Preferred Stock was to be converted into 1,000 shares of Issuer Common Stock, subject to certain limitations, on January 17, 2023. The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023.
- 3. NQ POF V GP, Ltd. ("NovaQuest GP") has the power to vote and dispose of any securities directly owned by NovaQuest. NovaQuest GP's investment committee makes voting and investment decisions regarding securities held by NovaQuest. NovaQuest GP disclaims beneficial ownership of any securities held by NovaQuest except to the extent of its pecuniary interest therein.

(Last)

(Street) **RALEIGH** 

(City)

The Issuer announced on January 17, 2023 that it changed its name from Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) to Aceragen, Inc. (Nasdaq: ACGN). The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Ronald J. Wooten serves on the board of directors of Issuer and is also a member of the investment committee of NovaQuest GP, which is the general partner of NovaQuest. NovaQuest GP has the power to vote and dispose of any securities directly owned by NovaQuest. NovaQuest GP is investment committee makes voting and investment decisions regarding securities held by NovaQuest. NovaQuest GP disclaims beneficial ownership of any securities held by NovaQuest except to the extent of its pecuniary interest therein.

/s/ S. Halle Vakani, Attorney-in-Fact for NQ POF V GP, Ltd.

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.